drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Approved HER2-directed antibody–drug conjugate that, after binding and internalization via HER2, releases the microtubule inhibitor DM1; preserves trastuzumab’s HER2 blockade and Fc-mediated ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted monoclonal antibody (trastuzumab) linked to the maytansinoid DM1. After binding HER2 on tumor cells and internalization, lysosomal processing releases DM1, a microtubule inhibitor that induces mitotic arrest and apoptosis; concurrently retains trastuzumab’s HER2 signaling blockade and Fc-mediated ADCC.
drug_name
T-DM1 (ado-trastuzumab emtansine)
nct_id_drug_ref
NCT06316531